BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35623961)

  • 1. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Hoeller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
    Eur J Cancer; 2022 Jul; 170():256-284. PubMed ID: 35623961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
    Eur J Cancer; 2020 Feb; 126():159-177. PubMed ID: 31866016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Bastholt L; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos AJ; Pehamberger H; Eggermont AM; ; ;
    Eur J Cancer; 2016 Aug; 63():201-17. PubMed ID: 27367293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Spatz A; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos A; Pehamberger H; Eggermont AM; ; ;
    Eur J Cancer; 2012 Oct; 48(15):2375-90. PubMed ID: 22981501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
    Eur J Cancer; 2020 Feb; 126():141-158. PubMed ID: 31928887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Höller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
    Eur J Cancer; 2022 Jul; 170():236-255. PubMed ID: 35570085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which adjuvant treatment for patients with BRAF
    Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
    Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Spatz A; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos A; Pehamberger H; Eggermont A
    Eur J Cancer; 2010 Jan; 46(2):270-83. PubMed ID: 19959353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
    Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
    Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
    Stratigos A; Garbe C; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Becker JC; Zalaudek I; Saiag P; Middleton MR; Bastholt L; Testori A; Grob JJ; ; ;
    Eur J Cancer; 2015 Sep; 51(14):1989-2007. PubMed ID: 26219687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.